Jacobs & Co. CA boosted its position in Synopsys, Inc. (NASDAQ:SNPS - Free Report) by 5.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,540 shares of the semiconductor company's stock after acquiring an additional 1,274 shares during the quarter. Jacobs & Co. CA's holdings in Synopsys were worth $10,095,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ameriflex Group Inc. acquired a new position in Synopsys during the fourth quarter valued at approximately $29,000. Whipplewood Advisors LLC acquired a new position in shares of Synopsys during the 4th quarter valued at $33,000. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Synopsys during the 4th quarter valued at $34,000. Sierra Ocean LLC acquired a new position in shares of Synopsys during the 4th quarter valued at $39,000. Finally, Hazlett Burt & Watson Inc. lifted its stake in shares of Synopsys by 28.6% during the fourth quarter. Hazlett Burt & Watson Inc. now owns 90 shares of the semiconductor company's stock worth $44,000 after purchasing an additional 20 shares in the last quarter. Institutional investors and hedge funds own 85.47% of the company's stock.
Insider Transactions at Synopsys
In other Synopsys news, CEO Sassine Ghazi sold 11,366 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $463.75, for a total transaction of $5,270,982.50. Following the transaction, the chief executive officer now owns 70,922 shares of the company's stock, valued at approximately $32,890,077.50. This trade represents a 13.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Geus Aart De sold 15,705 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $444.42, for a total transaction of $6,979,616.10. Following the transaction, the insider now directly owns 116,671 shares in the company, valued at approximately $51,850,925.82. The trade was a 11.86% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.62% of the company's stock.
Synopsys Price Performance
SNPS traded up $5.09 during trading on Friday, hitting $460.08. The company had a trading volume of 3,356,054 shares, compared to its average volume of 1,143,644. The company has a market cap of $71.14 billion, a PE ratio of 31.69, a P/E/G ratio of 3.23 and a beta of 1.16. The business has a 50-day moving average of $453.46 and a 200-day moving average of $486.08. Synopsys, Inc. has a 1-year low of $365.74 and a 1-year high of $624.80.
Synopsys (NASDAQ:SNPS - Get Free Report) last issued its earnings results on Wednesday, May 28th. The semiconductor company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.27. Synopsys had a net margin of 36.12% and a return on equity of 20.48%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the business posted $3.00 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. Research analysts forecast that Synopsys, Inc. will post 10.64 earnings per share for the current year.
Wall Street Analysts Forecast Growth
SNPS has been the topic of a number of recent research reports. KeyCorp set a $575.00 price objective on Synopsys and gave the stock an "overweight" rating in a research note on Tuesday, May 20th. Rosenblatt Securities reduced their price target on Synopsys from $660.00 to $625.00 and set a "buy" rating on the stock in a research report on Thursday. Needham & Company LLC reissued a "buy" rating and set a $650.00 price target on shares of Synopsys in a research report on Thursday. Piper Sandler reissued an "overweight" rating and set a $615.00 target price (down from $653.00) on shares of Synopsys in a research report on Thursday. Finally, Mizuho reduced their target price on shares of Synopsys from $650.00 to $600.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 15th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Synopsys presently has a consensus rating of "Moderate Buy" and an average target price of $609.64.
Read Our Latest Stock Report on Synopsys
Synopsys Company Profile
(
Free Report)
Synopsys, Inc provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions.
Featured Stories

Before you consider Synopsys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Synopsys wasn't on the list.
While Synopsys currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.